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ConcordanceAbstract Background: The discordance in oestrogen receptor (ER), progesterone receptor
(PgR) and human epidermal growth factor receptor 2 (HER2) status between primary and
recurrent breast cancer is being intensively investigated and a large amount of data have been
produced. However, results from different studies are heterogeneous and often conﬂicting. To
highlight this issue, a meta-analysis of published data was performed.
Methods: A literature search was performed using Medline, and all the studies published from
1983 to 2011 comparing changes in ER, PgR and/or HER2 status in patients with matched
breast primary and recurrent tumours were included. We used random-effects models to esti-
mate pooled discordance proportions.
Results: We selected 48 articles, mostly reporting retrospective studies. Thirty-three, 24 and 31
articles were focused on ER, PgR and HER2 changes, respectively. A total of 4200, 2739 and
2987 tumours were evaluated for ER, PgR and HER2 discordance, respectively. The hetero-
geneity between study-speciﬁc discordance proportions was high for ER (I2 = 91%,o, IL, 2
l.: +39
278 G. Aurilio et al. / European Journal of Cancer 50 (2014) 277–289p < 0.0001), PgR (I2 = 79%, p < 0.0001) and HER2 (I2 = 77%, p < 0.0001). Pooled discor-
dance proportions were 20% (95% conﬁdence interval (CI): 16–35%) for ER, 33% (95% CI:
29–38%) for PgR and 8% (95% CI: 6–10%) for HER2. Pooled proportions of tumours shifting
from positive to negative and from negative to positive were 24% and 14% for ER
(p = 0.0183), respectively. The same ﬁgures were 46% and 15% for PgR (p < 0.0001), and
13% and 5% for HER2 (p = 0.0004).
Conclusion: Our ﬁndings strengthen the concept that changes in receptor expression may
occur during the natural history of breast cancer, suggesting clinical implications and a pos-
sible impact on treatment choice.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
Since the late 70s, and especially during the last
decade, the occurrence of phenotype discordance in hor-
mone receptor (oestrogen receptor (ER) and progester-
one receptor (PgR)) and human epidermal growth
factor receptor 2 (HER2) status between primary and
recurrent breast cancer has been repeatedly reported
[1,2]. This evidence sprang mostly from retrospective
analyses investigating ER, PgR and HER2 in heteroge-
neous sites of relapses, including local recurrences,
regional lymph nodes and distant metastases, although
a few studies prospectively evaluated the impact of
phenotype discordance in patients’ management (e.g.
treatment planning) and survival.
Reassessing the biological features of disease is not
currently considered mandatory, and has been largely
individualised, although recent international guidelines
encourage to perform biopsy of metastatic sites, mostly
when they represent the ﬁrst recurrence of disease and/
or ER/PgR/HER2 status is unknown or originally neg-
ative [National Comprehensive Cancer Network
(NCCN) guidelines 2012].
In order to shed light to this debated topic, we
performed a meta-analysis of the studies evaluating the
discordance rate in ER, PgR and HER2 status between
primary tumour and corresponding relapse.
2. Methods
2.1. Selection of studies
A literature search was performed through the Med-
ical Literature Analysis and Retrieval System Online
(MEDLINE) database (up to December 2011, including
three studies e-pub ahead of print in 2011 and published
in 2012), using the medical subject headings terms
‘Breast cancer’ and ‘Recurrence’, or ‘Neoplasm Metas-
tasis’ and ‘Receptors, Oestrogen’ or ‘Receptors, Proges-
terone’ or ‘Genes, erbB-2/HER2’. Moreover, the
reference lists of the papers of interest was manually
screened to ensure sensitivity of the search strategy
and to identify additional relevant studies. We limited
our search to studies published in English.Studies that reported changes in hormonal receptors
(ER and PgR) and/or HER2 status in patients with
matched primary breast tumour and recurrence tissues,
published as original articles, were selected. Abstracts,
letters, reviews and meta-analyses were not considered.
2.2. Data collection
The selected publications were independently
reviewed by two of the authors (D.D. and G.A.) to
determine the eligibility of each article in the meta-
analysis. Doubts or disagreement was resolved by
consensus among the two investigators. The following
details were extracted: total number of patients
evaluated, sites of relapse and ER, PgR and HER2
discordance rate. Whenever reported, we also recorded
the prevalence of patients whose ER, PgR and HER2
status shifted from positive to negative and vice versa.
The technique used to deﬁne the HER2 status, immuno-
histochemistry (IHC) and/or Fluorescent In Situ
Hybridisation (FISH) was also registered.
2.3. Statistical analysis
The proportion of ER, PgR and HER2 changes with
exact 95% conﬁdence intervals (CIs) was calculated for
each study. The Freeman–Tukey double arcsine trans-
formation was used for the calculation of pooled
estimates and corresponding 95% CIs [3,4]. Random-
eﬀects pooled estimates were calculated in order to take
into account heterogeneity between estimates [5].
Statistical heterogeneity among studies was evaluated
using the chi-square test statistic and was measured
using the I2 statistic, which is the proportion of total
variation contributed by between-study variance tao-
squared (s2) [6].
Chi-square statistics was used to test for diﬀerences of
summary estimates among subgroups [7]. Publication
bias was evaluated using funnel plots and the asymmetry
test developed by Egger and colleagues [8]. All analyses
were carried out with the SAS software (SAS Institute,
Cary, NC) and the R software (http://cran.r-pro-
ject.org/) with package ‘meta’. All the reported P values
were two sided.
Fig. 1. Flow-chart of selection strategy.
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Fig. 2. Forest plot for proportion of discordance oestrogen receptor (ER).
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Table 1
Pooled proportion of discordance oestrogen receptor (ER), progesterone receptor (PgR) and human epidermal growth factor receptor 2 (HER2) by
relapse site.
Any discordance LR DM p-Value*
N Pooled (conﬁdence interval (CI) 95%) N Pooled (CI 95%)
ER 15 0.16 (0.11–0.22) 15 0.23 (0.16; 0.30) 0.13
PgR 9 0.26 (0.21–0.32) 12 0.41 (0.37; 0.45) <0.0001
HER2 12 0.06 (0.03–0.09) 18 0.10 (0.07; 0.14) 0.039
LR: loco-regional, DM: distant metastases.
* p-Value of test of heterogeneity between groups.
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Forty-eight studies were identiﬁed (Fig. 1, [9–56]) and
their main characteristics are reported in the Appendix.
ER, PgR and HER2 status in the primary tumour and
corresponding relapses were available in 33, 24 and 31
studies, respectively. The discordance rate was assessed
in 4200 patients for ER, 2987 patients for HER2 and
2739 patients for PgR. There was no evidence for publi-
cation bias for ER, PgR and HER2 (Egger’s test:
p = 0.17, p = 0.55 and p = 0.38, respectively. Supple-
mentary Fig. 1).
3.1. Evaluation of ER
Fig. 2 shows the discordance proportions reported
for ER in each study included in the analysis. The heter-
ogeneity between proportions ranged from 3% [37] to
62% [44] (I2 = 91%, s2 = 0.08, p < 0.0001). The meta-
analytic pooled discordance proportion was 20% (95%
CI: 16–35%). Stratiﬁed analysis performed according
to the site of relapse revealed similar pooled discordance
proportions across strata (p = 0.13, Table 1). The
pooled discordance proportions in prospective and
retrospective studies were respectively 29% (95% CI:
15–46%) and 19% (95% CI: 15–24%) (p = 0.23). Fig. 3
shows the proportions of patients whose tumour ER sta-
tus changed from positive to negative (Fig. 3A), and
from negative to positive (Fig. 3B). The pooled propor-
tion of negative and positive conversion was 24% (95%
CI: 9–20%) and 14% (95% CI: 9–20%), respectively
(p = 0.02).
3.2. Evaluation of PgR
Fig. 4 shows the discordance proportions reported
for PgR in each study included in the analysis.
The heterogeneity between proportions ranged from
12% [17] to 54% [47] (I2 = 79%, s2 = 0.04, p < 0.0001).
The meta-analytic pooled discordance proportion was
33% (95% CI: 29–38%). Stratiﬁed analysis performed
according to the site of relapse revealed diﬀerent pooled
discordance proportions across strata (p < 0.0001,
Table 1). The highest pooled discordance proportion
was 41% (95% CI: 37–45%) in studies comparing
primary tumours and distant metastases, while the sameﬁgure was 26% (95% CI: 21–32%) in studies comparing
primary tumours and loco-regional relapse. The pooled
discordance proportions in prospective and retrospec-
tive studies were respectively 37% (95% CI: 25–50%)
and 33% (95% CI: 28–37%) (p = 0.49).
Fig. 5 shows the proportions of patients whose
tumour PgR status changed from positive to negative
(Fig. 5A), and from negative to positive (Fig. 5B). The
pooled proportion of negative and positive conversion
was 46% (95% CI: 37–55%) and 15% (95% CI:
12–17%), respectively (p < 0.0001).
3.3. Evaluation of HER2
Fig. 6 shows the discordance proportions reported
for HER2 in each study included in the analysis. The
heterogeneity between proportions ranged from 0%
[13,20,22,29] to 24% [30] (I2 = 77%, s2 = 0.03,
p < 0.0001).
The meta-analytic pooled discordance proportion was
8% (95% CI: 6–10%). Stratiﬁed analysis conducted
according to the site of relapse revealed diﬀerent pooled
discordance proportions across strata: in particular, the
pooled discordance proportion with respect to the pri-
mary tumour was 10% for distant metastases (95% CI:
7–14%), and 6% for loco-regional relapse (95% CI:
3–9%) (p = 0.039, Table 1). Diﬀerent pooled discordance
proportions across strata were found when the technique
used to deﬁne HER2 status was taken into account: the
pooled discordance proportion was 10% in studies using
IHC and FISH (95% CI: 7–12%) and 5% (95% CI: 2–
8%) in studies using IHC only (p = 0.02). The pooled dis-
cordance proportions in prospective and retrospective
studies were respectively 10% (95% CI: 4–18%) and 8%
(95% CI: 6–10%) (p = 0.61).
Fig. 7 shows the proportions of patients whose HER2
status changed from positive to negative (Fig. 7A), and
from negative to positive (Fig. 7B). The pooled propor-
tion of negative and positive conversion was 13% (95%
CI: 9–18%) and 5% (95% CI: 4–8%) (p = 0.0004). In par-
ticular, the pooled proportion of negative and positive
conversion was 15% (95% CI: 10–21%) and 7% (95%
CI: 5–10%) in studies using IHC and FISH, respectively
(p = 0.04), and 8% (95% CI: 4–13%) and 2% (95% CI: 1–
4%) in studies using IHC only, respectively (p = 0.001).
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Fig. 3. (A) Forest plot for proportion of negative conversion oestrogen receptor (ER). (B) Forest plot for proportion of positive conversion ER.
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Fig. 4. Forest plot for proportion of discordance progesterone receptor (PgR).
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The assessment of biological changes in metastatic
disease and the question whether and why a metastatic
deposit should be biopsied is still a debated topic in
breast cancer. In this study, we meta-analysed published
data on ER, PgR and HER2 status discordance between
primary breast cancer and recurrent tumours. Our meta-
analysis, that was unaﬀected by publication bias,
showed that the rates of discordance for ER, PgR and
HER2 were 20%, 33% and 8%, respectively. Since the
earlier studies reporting discordance in ER, PgR and
HER2 status between primary tumour and relapses have
been published, two alternative explanations arose,
pointing to technical issues, such as poor reproducibility
of the immunohistochemical technique, or to a true bio-
logical manifestation of tumour heterogeneity, a contro-
versy lasting more than 40 years and still unresolved.
The lack of a perfect reproducibility in the immunohis-
tochemical or FISH assessment of ER, PgR and HER2
status has been repeatedly reported in prospective trials
based on central pathology review [57,58], and a mathe-
matical model has been proposed foreseeing a discor-
dance rate of at least 10% even using an ideal test
yielding 95% accuracy, sensitivity and speciﬁcity, a sce-
nario reasonably far from the clinical practice, where
additional variables including time and type of ﬁxation,
sampling issues and misinterpretation of the results may
further aﬀect reproducibility [59].
Although clearly established, it is likely that the tech-
nical issue alone does not explain thoroughly the varia-tion of ER, PgR and HER2 status between primary
tumours and relapses observed in our meta-analysis. If
occurring as a consequence of an analytical ﬂaw, one
could expect that the discordance rates among the anti-
gens tested would be roughly the same, while actually
they were 20%, 33% and 8% for ER, PgR and HER2,
respectively. Furthermore, if the discrepancy was merely
technical, it seems conceivable that adding to IHC a
potentially more objective and reproducible tool like
FISH would signiﬁcantly reduce the discordance rate:
on the contrary, the HER2 discordance rate reported
in the present analysis was 10% in the studies using
IHC and FISH, and 5% in studies using IHC only. Like-
wise, we found that the prevalence of negative conver-
sion outnumbered that of positive conversion (24%
versus 14%, 46% versus 15%, 13% versus 5%, for ER,
PgR and HER2, respectively), while they would be very
similar if occurring by chance only for technical reasons.
Based on more than 4000 patients for ER, and almost
3000 for PgR and HER2, this highly statistically signif-
icant ﬁnding is in line with the notion that a large frac-
tion of patients originally carrying endocrine-responsive
or HER2-positive tumours eventually develop resistance
to their speciﬁc treatments, possibly as the result of a
selective selection fostering ER/PgR and HER2-nega-
tive tumour clones in the metastatic sites. Although
the loss of PgR immunoreactivity, that was the most fre-
quent change observed in our meta-analysis, does not
usually inﬂuence clinical decision making, it should be
taken into account since it may reﬂect a shifting to a
more aggressive phenotype with a documented reduced
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Fig. 5. (A) Forest plot for proportion of negative conversion progesterone receptor (PgR). (B) Forest plot for proportion of positive conversion
PgR.
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guidelines for optimising the immunohistochemical
analyses, coupled with the availability of detection kits
for ER, PgR and HER2, would have lowered the
discordance rate in most recent studies, while we
reported that the date of diagnosis did not signiﬁcantly
inﬂuence the discrepancy in ER, PgR and HER2 status
between primary tumour and bone metastases in a retro-
spective series of breast cancer patients whose primary
tumour characteristics were addressed by using diﬀerent
primary antibodies over a 12-year period [62]. Unfortu-
nately, most of the studies included in this meta-analysis
did not report details on the date of diagnosis andrelapse, thus preventing us from conﬁrming this ﬁnding
in a larger scale.
On the other hand, recent studies based on next gener-
ation sequencing shed new light on tumour heterogeneity,
reinforcing the hypothesis that variation in ER, PgR and
HER2 status may actually reﬂect clonal genome evolu-
tion. Tumour heterogeneity may be attributable to
tumour biological drift, selective pressure of therapy lead-
ing to clonal selection with the development of a novel
tumour cell clone, or the presence of small sub-clones rou-
tinely undetected within the primary tumour. Along this
line, as prospectively reported by Hilton and colleagues
[45] a signiﬁcant ER discordance rate between primary
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Fig. 6. Forest plot for proportion of discordance human epidermal growth factor receptor 2 (HER2).
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cordance amongmetastases arising inmultiple bone sites,
suggesting the occurrence of ametastasising clone diverg-
ing in terms of ER immunoreactivity from the primary
tumour. Whether and how ER, PgR and HER2 conver-
sion modiﬁes the treatment schedule and aﬀects breast
cancer patients survival has not been fully elucidated,
and the available data are scarce and conﬂicting, as well
as the optimal time to retest tumour biology. In this
regard, clinical judgment remains essential to guide a re-
assessment of tissue biology, for instance whenever the
metastasis occurs long after tumour diagnosis, arises dur-
ing an unusual clinical course with early and frequent
treatment failures or may guide the administration of
targeted therapies. As for survival outcomes, Amir and
colleagues [53] did not ﬁnd any signiﬁcant diﬀerence in
overall survival and time to treatment failure, while as
reported by Dieci and colleagues [63] negative conversion
of hormone receptors andHER2was signiﬁcantly associ-
ated to a reduced post-relapse survival and, for HER2
only, overall survival. In the same context, patients with
concordant receptor status (at least one receptor positive)
have been reported to have a signiﬁcantly improved post-
recurrence [42] or overall survival [64], pointing to a role
of hormonal receptor and/or HER2 change in the man-
agement of metastatic breast cancer patients [53,56,65].Along this line, the adding of trastuzumab has been
recently reported to improve survival in patients with
HER2-positive metastatic deposits which did not receive
a previous anti-HER2 therapy [66].
Unfortunately, relevant ethical constraints prevented
planning randomised prospective trials, which could
overcome these inconsistencies.
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Fig. 7. (A) Forest plot for proportion of negative conversion human epidermal growth factor receptor 2 (HER2). (B) Forest plot for proportion of
positive conversion HER2.
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Appendix ACharacteristics of studies included in the meta-analysis.
First author (year) Country Design Site
Holdaway (1983) [9] New Zealand R LR-DM
Mobbs (1987) [10] Toronto R LR-DM
Andersen (1988) [11] Denmark R LR-DM
Kamby (1989) [12] Denmark P LR-DM
Spataro (1992) [54] United States of
America (USA),
Switzerland,
Italy, Sweden
R LR-DM
Niehans (1993) [13] USA R LR-DM
Li (1994) [14] USA R LR-DM
Johnston (1995) [15] England R LR-DM
Nedergaard (1995) [16] Denmark R LR
van Agthoven (1995)
[17]
Netherlands R LR
Kuukasja¨rvi (1996)
[18]
Finland R LR-DM
Masood (2000) [19] USA R DM
Shimizu (2000) [20] Japan R LR-DM
Simon (2001) [21] Switzerland R LR
Tanner (2001) [22] Finland R LR-DM
Zheng (2001) [23] China R LR
Gancberg (2002) [24] Switzerland R DM
Vincent-Salomon
(2002) [25]
France R DM
Edgerton (2003) [26] USA R LR-DM
Iguchi (2003) [27] Japan R LR
Sekido (2003) [28] Japan R LR-DM
Carlsson (2004) [29] Sweden R LR
Regitnig (2004) [30] Austria R DM
Wang (2004) [31] China R DM
Gong (2005) [32] USA R LR-DM
Lower (2005) [33] USA R LR-DM
Zidan (2005) [34] Israel R LR-DM
Pectasides (2006) [35] Greece P DM
Tapia (2007) [36] Switzerland R DM
Line missingAppendix B. Supplementary data
Supplementary data associated with this article can
be found, in the online version, at http://dx.doi.org/
10.1016/j.ejca.2013.10.004.Oestrogen
receptor
(ER)
Progesterone
receptor
(PgR)
Human
epidermal
growth
factor
receptor 2
(HER2)
Fluorescent
In Situ
Hybridisation
(FISH) (yes/
no)
Yes Yes No –
Yes Yes No –
Yes No No –
Yes No No –
Yes No No –
No No Yes No
Yes Yes No –
Yes No No –
Yes No No –
Yes Yes No –
Yes Yes No –
No No Yes No
Yes Yes Yes No
No No Yes Yes
No No Yes Yes
Yes No No –
No No Yes No
No No Yes No
No No Yes Yes
Yes No No –
Yes Yes Yes Yes
No No Yes Yes
No No Yes Yes
Yes Yes Yes No
No No Yes Yes
Yes Yes No –
No No Yes Yes
No No Yes Yes
No No Yes Yes
Table (continued)
First author (year) Country Design Site Oestrogen
receptor
(ER)
Progesterone
receptor
(PgR)
Human
epidermal
growth
factor
receptor 2
(HER2)
Fluorescent
In Situ
Hybridisation
(FISH) (yes/
no)
Gomez-Fernandez
(2008) [37]
USA R LR-DM Yes No No –
Guarneri (2008) [38] Italy R LR-DM Yes Yes Yes Yes
Santinelli (2008) [39] Italy P LR-DM No No Yes Yes
Wu (2008) [40] USA R DM Yes Yes Yes Yes
Amir (2008) [44] Canada P DM Yes Yes No –
Broom (2009) [41] Canada R DM Yes Yes Yes Yes
Liedtke (2009) [42] USA R LR-DM Yes Yes Yes Yes
Idirisinghe (2010) [46] Singapore R LR-DM Yes Yes Yes No
Thompson (2010) [48] England P LR-DM Yes Yes Yes Yes
Aitken (2010) [43] England R LR Yes Yes Yes Yes
Sari (2011) [47] Turkey R LR-DM Yes Yes Yes Yes
Hilton (2011) [45] Canada P DM Yes Yes No –
Bogina (2011) [49] Italy R LR-DM Yes Yes Yes No
Curigliano (2011) [50] Italy R DM Yes Yes Yes Yes
Gong (2011) [51] USA R LR-DM Yes No No –
Wilking (2011) [52] Sweden R LR-DM No No Yes Yes
Amir (2012) [53] Canada P DM Yes Yes Yes Yes
Montagna (2012) [55] Italy R LR Yes Yes Yes No
Lindstro¨m (2012) [56] Sweden R LR-DM Yes Yes Yes Yes
LR: loco-regional; DM: distant metastases; P: prospective; R: retrospective.
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